Product Information
ZITUVIO 100 MG TABLET is a brand product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $10.0823 per EA under NDC 70710124203. Its NADAC has been published 81 times since Mar 19, 2025.
FDA first approved this application on Oct 18, 2023.
Strength
100 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710124203
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SITAGLIPTINApproval Type
New Drug (NDA)
FDA Application
NDA211566FDA Approved
10/18/2023
On Market Since
11/30/2023
Pharmacological Classes
Price Statistics
The NADAC for ZITUVIO 100 MG TABLET has been published 81 times since Mar 19, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.0823 per EA |
|---|---|
| All-time high | $10.0924 (May 14, 2025) |
| All-time low | $10.0700 (Jun 18, 2025) |
| 52-week high | $10.0890 |
| 52-week low | $10.0751 |
| Median price | $10.0807 |
| Average price | $10.0808 |
| Largest weekly change | -0.2% (May 21, 2025) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sitagliptin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sitagliptin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Dipeptidyl Peptidase 4 Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZITUVIO 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ZITUVIO 100 MG TABLET, manufactured by Zydus Pharmaceuticals (USA) Inc., is $10.0823 per EA (NDC 70710124203), effective Sep 30, 2026.
How has the price of ZITUVIO 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for ZITUVIO 100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for ZITUVIO 100 MG TABLET?
Since Mar 19, 2025, the NADAC for ZITUVIO 100 MG TABLET has ranged from a low of $10.0700 (Jun 18, 2025) to a high of $10.0924 (May 14, 2025), with a median of $10.0807 per EA.
Are there cheaper alternatives to ZITUVIO 100 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ZITUVIO 100 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZITUVIO 100 MG TABLET?
ZITUVIO 100 MG TABLET (NDC 70710124203) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a brand product.